Literature DB >> 16006802

Diffuse large B-cell lymphoma with extra Bcl-2 gene signals detected by FISH analysis is associated with a "non-germinal center phenotype".

Shigeru Kusumoto1, Yukio Kobayashi, Naohiro Sekiguchi, Kazuki Tanimoto, Yasushi Onishi, Yukiko Yokota, Takashi Watanabe, Akiko Miyagi Maeshima, Takashi Ishida, Hiroshi Inagaki, Yoshihiro Matsuno, Ryuzo Ueda, Kensei Tobinai.   

Abstract

Amplification and translocation of the Bcl-2 gene has been detected in a certain subset of diffuse large B-cell lymphomas (DLBCL). The correlations among Bcl-2 protein expression, gene translocation or amplification, and the molecular signature determined by cDNA array are poorly understood. This study examined 25 cases with de novo nodal DLBCL. Interphase fluorescence in situ hybridization (FISH) analysis was performed to evaluate the Bcl-2 gene using IGH/BCL2 and CEP18 centromere probes (Vysis). When extra Bcl-2 gene signals were observed in each tumor cell and when these signals were in proportion to the extra CEP18 probe signals, we regarded the findings as indicating the presence of an additional chromosome 18; when extra Bcl-2 signals were observed but additional CEP18 signals were not, we regarded the findings as indicating the presence of gene amplification. A panel of 3 antigens (CD10, Bcl-6, and MUM-1) was applied to categorize each case as either a "germinal center B-cell (GCB) phenotype" or a "non-GCB phenotype." Of the 25 cases examined, 8 cases (32%) were classified as "GCB phenotype" and 17 cases (68%) were classified as "non-GCB phenotype." A FISH analysis revealed that t(14;18) was detected in 2 of the 8 cases (25%) with the "GCB phenotype" but in none of the 17 "non-GCB phenotype" cases. Extra Bcl-2 gene signals were detected in 7 of the 25 (28%) cases examined: n = 5 for an additional chromosome 18, n = 1 for gene amplification, and n = 1 for additional chromosome 18 + gene amplification. Extra Bcl-2 gene signals were exclusively detected in DLBCL with the "non-GCB phenotype"; these cases, with the exception of one, stained strongly positive for Bcl-2. The DLBCLs with Bcl-2 protein overexpression were classified into at least two heterogeneous molecular groups, based on the results of the FISH analysis.

Entities:  

Mesh:

Year:  2005        PMID: 16006802

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  8 in total

1.  Prognostic significance of B-cell differentiation genes encoding proteins in diffuse large B-cell lymphoma and follicular lymphoma grade 3.

Authors:  Ana Borovecki; Petra Korać; Marin Nola; Davor Ivanković; Branimir Jaksić; Mara Dominis
Journal:  Croat Med J       Date:  2008-10       Impact factor: 1.351

2.  Prognostic significance of miR-34a and its target proteins of FOXP1, p53, and BCL2 in gastric MALT lymphoma and DLBCL.

Authors:  Miaoxia He; Li Gao; Shimin Zhang; Liyang Tao; Jianjun Wang; Jianmin Yang; Minghua Zhu
Journal:  Gastric Cancer       Date:  2013-11-14       Impact factor: 7.370

3.  Clinicopathological prognostic factors of 24 patients with B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma.

Authors:  Ken-Ichi Miyamoto; Yukio Kobayashi; Akiko Miyagi Maeshima; Hirokazu Taniguchi; Junko Nomoto; Hideaki Kitahara; Suguru Fukuhara; Wataru Munakata; Dai Maruyama; Kensei Tobinai
Journal:  Int J Hematol       Date:  2016-04-19       Impact factor: 2.490

4.  B-cell lymphomas with concurrent MYC and BCL2 abnormalities other than translocations behave similarly to MYC/BCL2 double-hit lymphomas.

Authors:  Shaoying Li; Adam C Seegmiller; Pei Lin; Xuan J Wang; Roberto N Miranda; Sharathkumar Bhagavathi; L Jeffrey Medeiros
Journal:  Mod Pathol       Date:  2014-08-08       Impact factor: 7.842

5.  Non-Hodgkin lymphoma (NHL) subtypes defined by common translocations: utility of fluorescence in situ hybridization (FISH) in a case-control study.

Authors:  Cindy M Chang; Jane C Schroeder; Wen-Yi Huang; Cherie H Dunphy; Ralph S Baric; Andrew F Olshan; Kathleen C Dorsey; Georgette A Dent; James R Cerhan; Charles F Lynch; Nathaniel Rothman; Kenneth P Cantor; Aaron Blair
Journal:  Leuk Res       Date:  2009-06-07       Impact factor: 3.156

6.  Prognostic Significance of in situ Phenotypic Marker Expression in Diffuse Large B-cell Lymphomas.

Authors:  Alexandar Tzankov; Philip Went; Stephan Dirnhofer
Journal:  Biomark Insights       Date:  2007-11-11

7.  Efficacy of dose-adjusted EPOCH plus rituximab/R-CHOP regimens and the prognosis analysis in patients with MYC, BCL2/BCL6 gene copy number gain lymphoma and double-hit lymphoma: results from a single institution retrospective clinical study.

Authors:  Qianwen Ma; Yu Chang; Ling Li; Xin Li; Xinhua Wang; Jingjing Wu; Xiaorui Fu; Zhenchang Sun; Hui Yu; Xudong Zhang; Zhiyuan Zhou; Feifei Nan; Zhaoming Li; Xiyang Liu; Qian Zhao; Yang Li; Lan Zhang; Mingzhi Zhang; Lei Zhang
Journal:  Cancer Manag Res       Date:  2019-02-11       Impact factor: 3.989

8.  Immunohistochemical and molecular characteristics with prognostic significance in diffuse large B-cell lymphoma.

Authors:  Carmen Bellas; Diego García; Yolanda Vicente; Linah Kilany; Victor Abraira; Belen Navarro; Mariano Provencio; Paloma Martín
Journal:  PLoS One       Date:  2014-06-02       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.